Block Copolymer Micelles Target Auger Electron Radiotherapy to the Nucleus of HER2-Positive Breast Cancer Cells

被引:50
|
作者
Hoang, Bryan [1 ]
Reilly, Raymond M. [1 ,3 ,4 ]
Allen, Christine [1 ,2 ,5 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
[2] Univ Toronto, Dept Chem, Toronto, ON M5S 3M2, Canada
[3] Univ Toronto, Dept Med Imaging, Toronto, ON M5S 3M2, Canada
[4] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada
[5] Univ Hlth Network, Princess Margaret Hosp, Radiat Med Program, STTARR Innovat Ctr, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
LOCALIZATION SIGNAL; MONOCLONAL-ANTIBODY; INTRACELLULAR DELIVERY; TRASTUZUMAB HERCEPTIN; ANTITUMOR-ACTIVITY; METHOTREXATE; PACLITAXEL; DOXORUBICIN; SEQUENCES; TRANSPORT;
D O I
10.1021/bm201479t
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Intracellular trafficking of Auger electron emitting radionuclides to perinuclear and nuclear regions of cells is critical to realizing their full therapeutic potential. In the present study, block copolymer micelles (BCMs) were labeled with the Auger electron emitter indium-111 (In-111) and loaded with the radiosensitizer methotrexate. HER2 specific antibodies (trastuzumab fab) and nuclear localization signal (NLS; CGYGPKKKRKVGG) peptides were conjugated to the surface of the BCMs to direct uptake in HER2 expressing cells and subsequent localization in the cell nucleus. Cell uptake and intracellular distribution of the multifunctional BCMs were evaluated in a panel of breast cancer cell lines with different levels of HER2 expression. Indeed cell uptake was found to be HER2 density dependent, confirming receptor mediated internalization of the,BCMs. Importantly, conjugation of NLS peptides to the surface of BCMs was found to result in a significant increase in nuclear uptake of the radionuclide In-111. Successful nuclear targeting was shown to improve the antipoliferative effect of the Auger electrons as measured by clonogenic assays. In addition, a significant radiation enhancement effect was observed by concurrent delivery of low-dose MTX and In-111 in all breast cancer cell lines evaluated.
引用
收藏
页码:455 / 465
页数:11
相关论文
共 50 条
  • [1] Multifunctional Block Copolymer Micelles for the Delivery of 111In to EGFR-Positive Breast Cancer Cells for Targeted Auger Electron Radiotherapy
    Fonge, Humphrey
    Lee, Helen
    Reilly, Raymond M.
    Allen, Christine
    MOLECULAR PHARMACEUTICS, 2010, 7 (01) : 177 - 186
  • [2] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [3] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [4] Steady Progress against HER2-Positive Breast Cancer
    Hayes, Daniel F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1336 - 1338
  • [5] Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm
    Soberino, Jesus
    Racca, Fabricio
    Perez-Garcia, Jose
    Garcia-Fernandez, Luis F.
    Cortes, Javier
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 248 - 258
  • [6] Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
    Mayer, Ingrid A.
    CLINICAL BREAST CANCER, 2009, 9 : S50 - S57
  • [7] Treatment strategy for HER2-positive breast cancer
    Mukai, Hirofumi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 335 - 340
  • [8] Frontiers in HER2-positive breast cancer in 2020
    Peddi, Parvin F.
    Slamon, Dennis J.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 48 - 52
  • [9] Progression and treatment of HER2-positive breast cancer
    Davoli, April
    Hocevar, Barbara A.
    Brown, Thomas L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 611 - 623
  • [10] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112